ANASTASIA SCHWAB: Open Payments
NPI 1730431610 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$559 in 16 payments from 11 companies in 2025. Trend: 2023 $215 · 2024 $288 · 2025 $559
Food & beverage: $559
| Company | Payments | Amount |
|---|---|---|
| Kerecis Limited | 1 | $150 |
| Ferring Pharmaceuticals Inc. | 1 | $97 |
| Blue Earth Diagnostics | 3 | $57 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| Janssen Biotech, Inc. | 2 | $45 |
| Boston Scientific Corporation | 2 | $43 |
| Merck Sharp & Dohme LLC | 1 | $35 |
| 180 Medical, Inc. | 1 | $29 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $27 |
| ABBVIE INC. | 1 | $20 |
Products named: Kerecis SurgiClose, ADSTILADRIN, POSLUMA, GEMTESA, ERLEADA, AMS 800 Artificial Urinary Sphincter, KEYTRUDA, JOURNAVX.
Industry payments across PA — which companies pay providers there.
